Merck
Merck chief defends ‘bumpy’ 2011
January 6, 2012Sales and Marketing Kenneth Frazier, Merck
Kenneth Frazier has defended his company’s ‘bumpy’ performance in 2011, and has highlighted key drugs for investors to watch. Frazier …
Merck and Roche begin combination hep C trial
December 16, 2011Research and Development, Sales and Marketing Copegus, Merck, Pegasys, Roche, Victrelis
Merck and Roche have started clinical trials to investigate combinations of their hepatitis C drugs. The first trial is designed …
Frazier defends R&D investment and attacks price pressure
December 14, 2011Research and Development, Sales and Marketing Merck, R&D productivity, prices
Merck & Co chief executive Kenneth Frazier has expressed concern that European governments increasingly want to pay unrealistically low prices …
NICE rejects Merck’s COPD drug Daxas
December 9, 2011Sales and Marketing COPD, Daxas, Merck, Nycomed
NICE has not recommended Merck’s COPD drug Daxas and is asking for a new clinical trial to test its effectiveness. …
Merck and Merck look to settle Facebook naming dispute
November 29, 2011Medical Communications Facebook, Merck, Merck KGaA
Merck & Co and Merck KGaA looked to have made inroads into their Facebook naming quarrel. Earlier this month Merck …
Onglyza cleared for use with insulin
November 29, 2011Sales and Marketing AstraZeneca, Merck, Onglyza, diabetes, insulin
European regulators have approved a licence extension for Bristol-Myers Squibb and AstraZeneca’s type II diabetes treatment Onglyza. The oral DPP-4 …
Merck pays $950 million to settle Vioxx charges
November 23, 2011Sales and Marketing Department of Justice, Merck, Vioxx, marketing violations, off label marketing
Merck will pay out $950 million and admit that it illegally marketed its painkiller Vioxx in the US. It will …
Merck’s vorapaxar fails in late-stage trial
November 15, 2011ACS, Brilinta, Efient, Merck, Plavix, antiplatelet, vorapaxar
Merck’s novel blood thinner vorapaxar has failed to meet its primary endpoint in a late-stage study.The TRACER trial compared vorapaxar …
Merck highlights updated pipeline
November 11, 2011Sales and Marketing CETP inhibitor, Merck, cholesterol, pipeline
Merck has showcased its most promising drug candidates, and says it expects to make eight US filings in the next …
Core products boost Merck’s results
October 31, 2011Medical Communications, Sales and Marketing Gardasil, Merck, Victrelis
Sales of core products and favourable exchange rates have helped Merck grow its revenue in a tough environment. Worldwide sales …
Abbott spin-off could attract mega merger
October 21, 2011Research and Development, Sales and Marketing Abbott, Bayer, Humira, Merck, Roche
Abbott’s new spin-off pharma firm could attract a lot of attention from big pharma looking to sure up their portfolios. …
Fresh scrutiny for new diabetes drugs
September 15, 2011Sales and Marketing Byetta, GLP-1, Januvia, Merck, Novo Nordisk, Victoza, diabetes
Merck’s Januvia and Lilly’s Byetta face renewed safety questions this week as the European Association for the Study of Diabetes …
Merck signs major deal with China’s Simcere
July 21, 2011Sales and Marketing Merck, Simcere, emerging markets
Merck is to establish a joint venture with China’s Simcere focused on serving China’s rapidly expanding health care needs by …
Roche and Merck collaborate on personalised cancer tests
June 8, 2011Research and Development Merck, Roche, personalised medicine
Roche has signed a deal to develop diagnostic tests for products in Merck’s oncology pipeline, in a bid to make …
Merck and Roche sign hepatitis C co-promotion deal
May 18, 2011Medical Communications, Sales and Marketing Merck, Roche, hepatitis C
Merck & Co and Roche have signed an agreement that will see them co-promote each other’s hepatitis C drugs in …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
